Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases
Authors' conclusion
We found that patients with SARDs had frequent breakthrough COVID-19, but the proportion experiencing severe COVID-19 was low.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) who received tixagevimab/cilgavimab preexposure prophylaxis (PrEP) between January 2, 2022, and November 16, 2022 (mean age 62.0 years, 78.2% female)
- Participants
- 444 patients
- Outcome
- Breakthrough COVID-19 after tixagevimab/cilgavimab
Methodological detailsmultivariable Cox regression
- Multivariable Cox regression
Main finding
As reported in the abstract
Breakthrough COVID-19
Breakthrough COVID-19 cases
83
18.7%
Incidence rate
31.5/1000 person-months
95% CI 24.70–38.24
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | |
|---|---|---|
| Breakthrough COVID-19 by age (risk factor) | aHR 0.86 per 10 years (95% CI 0.75–0.99) | |
| Breakthrough COVID-19 by baseline spike antibody level (risk factor)Spike antibody > 200 unitsvs Spike antibody < 0.4 units | aHR 0.42 (95% CI 0.18–0.99) | |
| Breakthrough COVID-19 by DMARD type (risk factor)CD20 inhibitor usersvs csDMARD usersSimilar risk | aHR 1.05 (95% CI 0.44–2.49) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Safety
Severe COVID-19 outcomes
- Hospitalizations
- 7 (1.6%)
- Deaths
- 1 (0.2%)
Original publication
Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases. J Rheumatol. Published 15 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →